Law and Regulations

At AAP 2025, Douglas Hoey, CEO of NCPA, discussed the possibility of PBM reform under the new administration and his take on Optum Rx’s plans to introduce a cost-plus reimbursement model.

At AAP 2025, Ron Friedman discussed best practices for responding to a DEA inspection, how to identify any red flags, and best practices for dispensing.

A conversation with Rob Frankil, RPh, executive director of the Philadelphia Association of Retail Druggists.

Explore key legislative actions changing pharmacy practice in 2025 and beyond.

Senators Elizabeth Warren and Tina Smith have reintroduced the Pharmaceutical Supply Chain Defense and Enhancement Act originally established in 2020.

Researchers reviewed Medicaid policies to understand vaccine coverage and reimbursement rates among physicians and pharmacists.

The Affordable Care Act was passed in 2010 to make health care and prescription medicine more accessible. Did it succeed?

Pharmacy experts from AON Pharmacy in Florida discussed the Inflation Reduction Act and how it affects reimbursement for Medicare Part D drugs.

Pharmacy law experts detailed the Drug Supply Chain Security Act, highlighting the role each entity within the supply chain plays in ensuring the safety and authenticity of US prescription drugs.

The Drug Enforcement Administration gives controlled substance licenses, and can just as easily take them away.

Current rules governing lawsuits must be revisited to strike a balance between legitimate and frivolous legal actions against health care providers.

The 70-plus-page lawsuit is directed at Express Scripts for its dealings with drug manufacturers in fueling the US opioid crisis.

Following the Federal Trade Commission’s interim report on PBMs, legislators are galvanized to make change happen.

The health care giant’s pharmacy benefit manager subsidiary filed a lawsuit claiming that the FTC’s recent 6(b) report was false and misleading.

McKesson, Cardinal Health, and Cencora will share the settlement payment, resolving claims that the companies were significantly involved in fueling the US opioid epidemic.

New prices will go into effect on January 1, 2026, for individuals covered by Medicare Part D prescription drugs.

Our congressional representatives have plenty of interaction with PBM lobbyists. It’s time they hear from patients as well.

An interim FTC report outlined how the rise of vertical integration and concentration has led to devastating results for both patients and fragile pieces of the health care delivery system.

Industry experts explored the increase in US prescription drug spending and how state spending targets come into play regarding patients’ rising out-of-pocket costs.

A Q&A with Douglas Hoey, CEO of NCPA, on how the new provision from CMS requiring DIR fees at the point of sale is impacting independent pharmacies in 2024.

See what's trending in pharmacy with a preview of the Total Pharmacy April issue.

This week, a divided America watched as the Supreme Court heard oral arguments regarding whether to reinstate restrictions on accessing mifepristone, an essential drug used in medication abortion.

As pharmacy benefit managers gain leverage to continue driving up drug prices, local pharmacies struggle to keep up and Congress has been called to act—but it might be too late.

Health care professionals, industry leaders, and politicians gathered for a virtual roundtable to discuss the state of the PBM industry.

The decision comes a year after a group of conservative attorneys generals threatened the chains with legal action.

How much longer can independent pharmacists survive with the current method of reimbursement?

The Congressional Budget Office last year estimated that price negotiation will lower average drug prices in Medicare and will reduce the budget deficit by $25 billion in 2031, including lowering Part D spending by $14 billion and Part B spending by $9 billion. Other federal spending will be lowered by $1 billion.

The Equitable Community Access to Pharmacist Services Act seeks to ensure that seniors in rural and underserved communities have access to care and services from pharmacists for common infectious diseases.

Just weeks after it gained FDA approval, pharmacy organizations have come forward to voice concerns about the safety and security of Florida’s drug importation program.